Neoplasms
Conditions
Keywords
Neoplasms, Colorectal
Brief summary
This study is a prospective observational cohort study. The study will be conducted in routine clinical practice settings. It is planned to enroll 1000 patients with metastatic Colorectal Cancer (mCRC) who have been previously treated with other approved treatments for metastatic disease and for whom a decision has been made by the physician to treat with regorafenib according to local health authority approved label. It is the aim of this observational cohort study to further characterize safety and effectiveness of regorafenib in routine clinical practice setting. Healthcare resource utilization in the routine provision of care is becoming increasingly important from a health economics and outcomes research perspective. Therefore, another aim of this observational cohort study is to capture healthcare resource associated with the management of treatment emergent adverse events in the real world setting. The primary objective of this study is to further characterize safety of regorafenib use in routine clinical practice settings. The secondary objective of this study is to assess the effectiveness of regorafenib in routine clinical practice settings as measured by Overall Survival (OS), Progression Free Survival (PFS) and Disease control rate (DCR). Health Related Quality of Life (HRQoL) Data will be collected in applicable countries.
Interventions
DRUGStivarga (Regorafenib, BAY73-4506)
Patients diagnosed with mCRC who have been previously treated with, or are not considered candidates for, other locally approved standard treatment(s) and for whom the decision has been made per investigator's routine treatment practice to prescribe regorafenib
Sponsors
Bayer
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients diagnosed with mCRC who have been previously treated with, or are not considered candidates for, other locally approved standard treatment(s) and for whom the decision has been made per investigator's routine treatment practice to prescribe regorafenib.
Exclusion criteria
* Patients participating in an investigational program with interventions outside of routine clinical practice
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of all treatment-emergent adverse events (TEAE) - Patients will be monitored for TEAE using the NCI-CTCAE Version 4.3 | Up to 42 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Disease control rate (DCR) - DCR is defined as percentage of patients, whose best response was not progressive disease (i.e. CR, PR or SD). Stable disease must be at least 6 weeks in duration. | Up to 42 months | — |
| Quality of Life - HRQoL using PRO questionnaire EQ-5D (8) in applicable countries | Up to 42 months | — |
| Healthcare resource utilization | Up to 42 months | Hospitalization (Date, Length), Concomitant medication and procedures and any other anticancer therapies |
| Overall Survival (OS), OS is defined as the time interval from the start of regorafenib therapy to death, due to any cause. | Up to 42 months | — |
| Progression free survival (PFS) is defined as the time interval measured from the day of start with regorafenib treatment to (radiological or clinical) progression or death, whichever comes first. | Up to 42 months | — |
Countries
Argentina, Austria, Czechia, Denmark, France, Italy, Luxembourg, Mexico, Netherlands, Singapore, Spain, Switzerland, Taiwan
Outcome results
None listed